Trial · NCT03359473
Adverse events160
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 160
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | Placebo- Female Participants | 6 | 23 | 6 |
| other | Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | GSK2881078 1.0 mg- Female Participants | 7 | 24 | 8 |
| other | Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | Placebo- Male Participants | 2 | 24 | 2 |
| other | Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | GSK2881078 2.0 mg- Male Participants | 3 | 25 | 4 |
| other | Epistaxis | Respiratory, thoracic and mediastinal disorders | Placebo- Female Participants | 0 | 23 | 0 |
| other | Epistaxis | Respiratory, thoracic and mediastinal disorders | GSK2881078 1.0 mg- Female Participants | 0 | 24 | 0 |
| other | Epistaxis | Respiratory, thoracic and mediastinal disorders | Placebo- Male Participants | 2 | 24 | 2 |
| other | Epistaxis | Respiratory, thoracic and mediastinal disorders | GSK2881078 2.0 mg- Male Participants | 1 | 25 | 1 |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Placebo- Female Participants | 1 | 23 | 1 |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | GSK2881078 1.0 mg- Female Participants | 0 | 24 | 0 |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Placebo- Male Participants | 1 | 24 | 1 |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | GSK2881078 2.0 mg- Male Participants | 0 | 25 | 0 |
| other | Pulmonary mass | Respiratory, thoracic and mediastinal disorders | Placebo- Female Participants | 0 | 23 | 0 |
| other | Pulmonary mass | Respiratory, thoracic and mediastinal disorders | GSK2881078 1.0 mg- Female Participants | 0 | 24 | 0 |
| other | Pulmonary mass | Respiratory, thoracic and mediastinal disorders | Placebo- Male Participants | 1 | 24 | 1 |
| other | Pulmonary mass | Respiratory, thoracic and mediastinal disorders | GSK2881078 2.0 mg- Male Participants | 1 | 25 | 1 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Placebo- Female Participants | 0 | 23 | 0 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | GSK2881078 1.0 mg- Female Participants | 3 | 24 | 5 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Placebo- Male Participants | 2 | 24 | 2 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | GSK2881078 2.0 mg- Male Participants | 2 | 25 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03359473/events